Analyst Ratings for Boston Scientific (BSX)
BSX Rating Summary
BSX Price Target Summary
- Highest: $9.50 (Wells Fargo)
- Lowest: $5.00 (Goldman Sachs)
- Average: $7.10
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$7.10 (-21.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/10/2013 | Wells Fargo | Upgrade | Outperform (Market Perform) |
9.50 (7.50) |
8.30 | 9.08 | 9.4% | Details |
| 4/26/2013 | Credit Suisse | Upgrade | Outperform (Neutral) |
N/A (N/A) |
7.54 | 9.08 | 20.42% | Details |
| 12/14/2012 | Barclays | Upgrade | Overweight (Equalweight) |
7.00 (6.00) |
5.63 | 9.08 | 61.28% | Details |
| 12/3/2012 | JMP Securities | Upgrade | Market Outperform (Market Perform) |
9.00 (N/A) |
5.54 | 9.08 | 63.9% | Details |
| 11/27/2012 | Bernstein | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
5.66 | 9.08 | 60.42% | Details |
| 11/26/2012 | Citi | Upgrade | Buy (Neutral) |
N/A (N/A) |
5.59 | 9.08 | 62.43% | Details |
| 11/20/2012 | Stifel Nicolaus | New Coverage | Buy (N/A) |
6.50 (N/A) |
5.21 | 9.08 | 74.28% | Details |
| 9/18/2012 | Leerink Swann | Downgrade | Market Perform (Outperform) |
6.00 (6.00) |
5.78 | 9.08 | 57.09% | Details |
| 7/27/2012 | Northland Securities | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
4.97 | 9.08 | 82.7% | Details |
| 12/22/2011 | Mizuho Securities | Downgrade | Neutral (N/A) |
5.40 (N/A) |
5.21 | 9.08 | 74.28% | Details |
| 12/15/2011 | Goldman Sachs » Updated 2/3/2012 |
Downgrade | Sell (N/A) |
5.00 (N/A) |
5.13 | 9.08 | 77% | Details |
| 10/18/2011 | Cowen | New Coverage | Neutral (N/A) |
N/A (N/A) |
5.55 | 9.08 | 63.6% | Details |
| 9/27/2011 | JPMorgan | Upgrade | Neutral (N/A) |
7.50 (N/A) |
5.93 | 9.08 | 53.12% | Details |
| 9/22/2011 | Kaufman Bros. | New Coverage | Hold (N/A) |
7.00 (N/A) |
5.93 | 9.08 | 53.12% | Details |
| 8/24/2011 | Morgan Keegan | Downgrade | Market Perform (N/A) |
7.00 (N/A) |
6.34 | 9.08 | 43.22% | Details |
